Abstract Introduction Hepatocellular carcinoma (HCC) is the 6th most common malignancy worldwide with variable prognostic outcomes. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential prognostic marker, but its applicability across Barcelona Clinic Liver Cancer (BCLC) stages remains unclear. This study aims to assess the prognostic value of NLR in patients with HCC across different BCLC stages. Materials and methods We conducted a multicenter retrospective analysis of 312 HCC patients in BCLC stage 0-A diagnosed and treated between 2010 and 2016 in eight centers in Slovakia. Patients were divided into BCLC stages 0-A, B, and C and further stratified by NLR < 1.5 and NLR ≥ 1.5. Results Overall survival (OS) and progression-free survival (PFS) were analyzed, with comparisons across stages and NLR subgroups. Patients with NLR < 1.5 were trending toward improved OS in each BCLC stage, with significant differences observed in stages BCLC B (40.1 vs. 16.9 months; P = 0.002) and BCLC C (18.93 vs. 5.78 months; P = 0.0028). In BCLC stage B, NLR < 1.5 was associated with a twofold increase in PFS compared to NLR ≥ 1.5 (40.1 vs. 16.9 months; P = 0.061). BCLC stage C patients with NLR < 1.5 achieved OS outcomes comparable to BCLC stage B patients with NLR ≥ 1.5 (18.9 vs. 16.9 months; P = 0.71). Conclusion Lower NLR was associated with better survival outcomes across BCLC stages, supporting its use as a prognostic marker in HCC. Future prospective studies are needed to confirm these findings and to determine optimal NLR cut-offs for clinical practice.
Šafčák et al. (2026) studied this question.